Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes
Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.
1. A virus-like particle comprising a chimeric human immunodeficiency virus (HIV)-Env polypeptide comprising a mouse mammary tumor virus (MMTV) transmembrane domain and cytoplasmic tail.
2. The virus-like particle of claim 1 , wherein the shell of the virus-like particle comprises 2% to 50% of chimeric HIV-Env polypeptide.
3. The virus-like particle of claim 1 , wherein the virus-like particle has Env-specific epitopes exposed on the outer surface thereof.
4. The virus-like particle of claim 1 , wherein the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody.
5. A virus-like particle comprising a chimeric human immunodeficiency virus (HIV)-Env polypeptide wherein the virus-like particle is produced by cotransfecting a eukaryotic host cell with a first expression vector and a second expression vector, wherein the first expression vector expresses an HIV-1 gag polypeptide, and wherein the second expression vector expresses a chimeric HIV-Env polypeptide, the second expression vector comprising an expression promoter operably linked to a recombinant nucleic acid encoding, wherein the recombinant nucleic acid comprises a first domain encoding a heterologous signal peptide, wherein the first domain is operably linked to a second domain encoding an HIV-Env polypeptide region, and a third domain encoding a polypeptide region selected from the group consisting of a heterologous transmembrane region, a heterologous cytoplasmic tail region, and a combination of a heterologous transmembrane region and a heterologous cytoplasmic tail region wherein the third domain encodes a polypeptide comprising one of the amino acid sequences SEQ ID NOs.: 2 and 7; and allowing the cotransfected host cell to form the virus-like particles.
6. The virus-like particle of claim 5 , wherein the virus-like particles are isolated by centrifugation.
7. The virus-like particle of claim 5 , wherein the first domain of the second expression vector encodes a signal peptide derived from honeybee mellitin.
8. The virus-like particle of claim 7 , wherein the signal peptide derived from honeybee mellitin has the amino acid sequence according to SEQ ID NO.: 31.
9. The virus-like particle of claim 5 , wherein the second domain of the second expression vector encodes the chimeric HIV-1 Con-S ΔCFI Env polypeptide.
10. The virus-like particle of claim 5 , wherein the amino acid sequence of the heterologous transmembrane region is selected from one of the sequences according to SEQ ID NOs.: 1-5.
11. The virus-like particle of claim 5 , wherein the amino acid sequence of the heterologous cytoplasmic tail region is selected from one of the sequences according to SEQ ID NOs.: 6-11.
12. The virus-like particle of claim 5 , wherein the chimeric HIV-Env polypeptide comprises the amino acid sequences SEQ ID NO.: 31, the chimeric HIV-1 Con-S ΔCFI Env polypeptide, and one of SEQ ID NOs.: 2 and 7.
13. The virus-like particle of claim 5 , wherein the nucleic acid sequence encoding the chimeric HIV-Env polypeptide is codon optimized for expression in an insect cell.